{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:06:48Z","timestamp":1793934408087,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12350-023-03353-w","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:02:02Z","timestamp":1692619322000},"page":"2721-2735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Transthyretin amyloid cardiomyopathy disease burden quantified using 99mTc-pyrophosphate SPECT\/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours"],"prefix":"10.1016","volume":"30","author":[{"given":"Satoru","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Toshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-023-03353-w_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-023-03353-w_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-023-03353-w_bib4","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1007\/s12350-023-03353-w_bib5","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","article-title":"Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-023-03353-w_bib8","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib9","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12350-021-02806-4","article-title":"Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis","volume":"29","author":"Roshankar","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib10","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1007\/s12350-021-02857-7","article-title":"Volumetric evaluation of 99mTc-pyrophosphate SPECT\/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters","volume":"29","author":"Watanabe","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11604-021-01221-6","article-title":"Usefulness of quantitative 99mTc-pyrophosphate SPECT\/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis","volume":"40","author":"Ogasawara","year":"2022","journal-title":"Jpn J Radiol"},{"key":"10.1007\/s12350-023-03353-w_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12350-022-02988-5","article-title":"Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis","volume":"30","author":"Avalon","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12350-022-03137-8","article-title":"Treatment response to Tafamidis quantitatively assessed by serial bone scintigraphy in transthyretin amyloid cardiomyopathy","volume":"30","author":"Maeda-Ogata","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014954","article-title":"Complete resolution of technetium pyrophosphate uptake after treatment of transthyretin cardiac amyloidosis","volume":"16","author":"Sperry","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"10.1007\/s12350-023-03353-w_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis: a novel imaging biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib18","doi-asserted-by":"crossref","unstructured":"Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, et al. Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019-30.","DOI":"10.1093\/ehjci\/jead030"},{"key":"10.1007\/s12350-023-03353-w_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","article-title":"Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis","volume":"64","author":"Papathanasiou","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-023-03353-w_bib20","doi-asserted-by":"crossref","unstructured":"Wollenweber T, Rettl R, Kretschmer-Chott E, Rasul S, Kulterer OC, Kluge K, et al. Cardiac DPD-uptake time dependency in ATTR patients verified by quantitative SPECT\/CT and semiquantitative planar parameters. J Nucl Cardiol. 2022:1-9.","DOI":"10.1007\/s12350-022-03149-4"},{"key":"10.1007\/s12350-023-03353-w_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41824-018-0035-1","article-title":"Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population","volume":"2","author":"Ramsay","year":"2018","journal-title":"Eur J Hybrid Imaging."},{"key":"10.1007\/s12350-023-03353-w_bib22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2967\/jnumed.113.133801","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis","volume":"55","author":"Pak","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-023-03353-w_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","article-title":"Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis","volume":"30","author":"Kessler","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s12350-019-01893-8","article-title":"Quantitative 99mTc-DPD SPECT\/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores","volume":"27","author":"Caobelli","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jcmg.2015.07.013","article-title":"Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction","volume":"8","author":"Sengelov","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"10.1007\/s12350-023-03353-w_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s12350-016-0768-9","article-title":"Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes","volume":"25","author":"Vranian","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib30","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1007\/s12350-023-03353-w_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12350-016-0478-3","article-title":"National patterns in imaging utilization for diagnosis of cardiac amyloidosis: a focus on Tc99m-pyrophosphate scintigraphy","volume":"24","author":"Harb","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib33","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-023-03353-w_bib35","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s12350-020-02205-1","article-title":"Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: comparison of quantitative and semi-quantitative approaches","volume":"27","author":"Regis","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib36","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-023-03353-w_bib37","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s12350-020-02455-z","article-title":"Addendum to ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"28","author":"Dorbala","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-023-03353-w_bib38","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","article-title":"Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis","volume":"23","author":"Castano","year":"2016","journal-title":"J Nucl Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-023-03353-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-023-03353-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124002150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124002150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-023-03353-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:16:04Z","timestamp":1761027364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358124002150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1071358124002150"],"URL":"https:\/\/doi.org\/10.1007\/s12350-023-03353-w","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin amyloid cardiomyopathy disease burden quantified using 99mTc-pyrophosphate SPECT\/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-023-03353-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}